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OBJECTIVES The purpose of this study was to determine whether lowering homocysteine levels with folic
acid, with or without antioxidants, will improve endothelial dysfunction in patients with
coronary artery disease (CAD).
BACKGROUND Elevated plasma homocysteine levels are a risk factor for atherosclerosis. Homocysteine may
promote atherogenesis through endothelial dysfunction and oxidative stress.
METHODS In a double-blind, placebo-controlled, randomized trial, we used vascular ultrasound to assess
the effect of folic acid alone or with antioxidants on brachial artery endothelium-dependent
flow-mediated dilation (FMD). Seventy-five patients with CAD (screening homocysteine
level $9 mmol/liter) were randomized equally to one of three groups: placebo, folic acid alone
or folic acid plus antioxidant vitamins C and E. Patients were treated for four months. Plasma
folate, homocysteine, FMD and nitroglycerin-mediated dilation were measured before and
after four months of treatment.
RESULTS Plasma folate, homocysteine and FMD were unchanged in the placebo group. Compared
with placebo, folic acid alone increased plasma folate by 475% (p , 0.001), reduced plasma
homocysteine by 11% (p 5 0.23) and significantly improved FMD from 3.2 6 3.6% to 5.2 6
3.9% (p 5 0.04). The improvement in FMD correlated with the reduction in homocysteine
(r 5 0.5, p 5 0.01). Folic acid plus antioxidants increased plasma folate by 438% (p , 0.001),
reduced plasma homocysteine by 9% (p 5 0.56) and insignificantly improved FMD from
2.6 6 2.4% to 4.0 6 3.7% (p 5 0.45), as compared with placebo. Nitroglycerin-mediated
dilation did not change significantly in any group.
CONCLUSIONS Folic acid supplementation significantly improved endothelial dysfunction in patients with
coronary atherosclerosis. Further clinical trials are required to determine whether folic acid
supplementation may reduce cardiovascular events. (J Am Coll Cardiol 2000;36:758 – 65)
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There is substantial epidemiologic evidence linking mild
hyperhomocysteinemia with atherosclerosis in the coronary,
cerebral and peripheral arteries (1–3). Despite a number of
negative prospective trials (4–6), the evidence overall indi-
cates that hyperhomocysteinemia is an independent risk
factor for atherosclerosis (7). Similar to cholesterol, the
association between plasma homocysteine and atherosclero-
sis appears to be graded, starting at values within the
“normal” range, rather than having a threshold effect (1,8,9).
A recent Norwegian study found a strong and graded
relation between plasma homocysteine levels .9 mmol/liter
and mortality in patients with coronary artery disease
(CAD) (10).
Experimental evidence suggests that homocysteine may
promote atherogenesis through its toxic effects on the
vascular endothelium (11–13), which is likely mediated
through oxidative stress (14). In humans, there is evidence
that chronic hyperhomocysteinemia is associated with im-
paired endothelium-dependent flow-mediated vasodilation
of the brachial artery (15–17).
Folic acid, alone or combined with other B vitamins, is
safe and effective in lowering plasma homocysteine levels
(18–25). Moreover, antioxidant vitamins, such as vitamins
C and E, may have an adjunctive role in preventing
homocysteine-mediated oxidative vascular injury (3,26–29).
Observational studies suggest that B vitamins may reduce
cardiovascular risk (30) and the extent of carotid atheroscle-
rosis (9,31). However, there is no evidence, based on
randomized, controlled trials, that folic acid supplementa-
tion, alone or with antioxidant vitamins, will reduce the risk
of cardiovascular disease. Although large-scale, randomized
trials to test this hypothesis are under way (32), smaller
intervention trials using surrogate vascular end points may
be of value (7,33). Accordingly, this clinical trial aimed to
test the hypothesis that lowering plasma homocysteine
levels with folic acid, alone or with antioxidant vitamins C
and E, would improve impaired endothelium-dependent
brachial artery flow-mediated dilation (FMD) in patients
with established CAD and normal or mildly elevated levels
of plasma homocysteine.
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METHODS
Study design and group. The study was a randomized,
double-blind, placebo-controlled, parallel-design trial con-
ducted between March 1998 and February 1999. The
protocol was approved by the Research Ethics Committee
of the Queen Elizabeth II Health Sciences Centre.
Patients undergoing cardiac catheterization at the Queen
Elizabeth II Health Sciences Centre were screened for entry
into the trial. Patients between 18 and 75 years of age were
eligible if they had angiographically proven CAD, defined
as $50% stenosis of the lumen diameter in a major
epicardial coronary vessel and a screening fasting plasma
total homocysteine level $9 mmol/liter within four weeks of
randomization. Patients were excluded if they had unstable
angina or myocardial infarction within two months of
screening, the need for coronary artery bypass graft surgery,
uncontrolled hypertension, diabetes mellitus, fasting total
cholesterol level .7.2 mmol/liter (278 mg/dl), requirements
for folic acid supplementation or pernicious anemia. Pa-
tients on folic acid, B vitamins, multivitamins or antioxi-
dants within four weeks of randomization were excluded.
All patients gave written, informed consent. Of the 166
consecutive patients screened, 91 were excluded (80 had a
screening homocysteine level ,9 mmol/liter and 11 refused
to participate). The remaining 75 patients were enrolled and
underwent baseline endothelial function and biochemical
assessment before randomization.
Noninvasive assessment of endothelial function. Long-
acting vasoactive medications were withheld for 24 h before
endothelial function testing, and smokers refrained from
smoking on the morning of the test. Patients were studied
after a 12-h overnight fast. Endothelium-dependent and
endothelium-independent dilation of the brachial artery was
assessed noninvasively using a high resolution ultrasound
system (Hewlett-Packard SONOS 2500) with a 7.5-MHz
linear-array vascular transducer, as previously described
(34–36). The brachial artery was imaged longitudinally, 2 to
15 cm above the antecubital crease, ensuring optimal visu-
alization of the anterior and posterior wall–lumen interfaces.
This position was maintained throughout the test, and a
similar position was used in the follow-up study. Baseline
images and pulsed Doppler flow velocity measurements
were taken. Next, a pneumatic tourniquet, placed proxi-
mally on the forearm, was inflated to 250 mm Hg of
pressure for 5 min and rapidly deflated, resulting in reactive
hyperemia. Doppler measurements were obtained immedi-
ately after deflation, and repeat brachial artery images were
continuously recorded for 120 s to assess the response to
reactive hyperemia. After 10 min of rest, brachial artery
scans were obtained before (second baseline) and after
administration of 0.3 mg of sublingual nitroglycerin to
assess endothelium-independent vasodilation. All images
were recorded on super VHS videotape for subsequent
quantitative analysis.
At each phase (baseline, 1 min after reactive hyperemia,
second baseline and 3 min after nitroglycerin), the end-
diastolic frames (coincident with the peak of the R wave)
from three consecutive cardiac cycles were digitized with a
Media 100 qx video card and Macintosh G3 computer.
Average end-diastolic brachial artery diameters were mea-
sured using the National Institutes of Health version
(NIH)-Image version 1.61 public domain software by one
observer who had no knowledge of the treatment assign-
ment and the protocol stage. Unless the intima–lumen
border was clearly defined, the media–lumen border for the
anterior and posterior walls was manually traced over a 10-
to 20-mm straight arterial segment, and the average diam-
eter over this segment was determined (35). Measurements
of the three sequential frames were averaged for each phase.
Endothelium-dependent FMD was calculated as the per-
cent change in brachial artery diameter after reactive hyper-
emia, as compared with the baseline value (intrasubject
coefficient of variation 2.1%). Endothelium-independent
nitroglycerin-mediated dilation (NMD) was calculated as
the percent change in brachial artery diameter after nitro-
glycerin, as compared with the second baseline value.
Brachial artery flow was calculated as the product of the
Doppler velocity–time integral, heart rate and brachial
artery cross-sectional area (pD2/4), where D 5 average
arterial diameter at that phase. Reactive hyperemia was
calculated as the percent change in arterial flow after
tourniquet deflation, as compared with the baseline value.
Biochemical analyses. Venous blood was collected from
the fasting subjects into vacutainers containing EDTA
(plasma total homocysteine, folate, vitamin B12 and malon-
dialdehyde [MDA]) and serum-separating gel (serum lipids
and creatinine) at baseline and follow-up. Samples were
collected on ice, and plasma was separated within 15 min
and frozen at 270°C for subsequent analysis. Screening
homocysteine levels were measured at the Queen Elizabeth
II Health Sciences Centre, while baseline and follow-up
homocysteine levels were measured at the Institut de Re-
cherches Cliniques de Montre´al by high performance liquid
chromatography and fluorescence detection, as previously
described (intra-assay coefficient of variation 2.3%; interas-
say coefficient of variation 2.5%) (37,38).
Plasma folate and vitamin B12 levels were measured
immunochemically on an Abbott IMx system (Abbott
Diagnostics, Abbott Park, Illinois). Serum lipid and creat-
inine levels were measured with a Beckman Synchron CX7
system (Beckman Coulter, Inc., Fullerton, California).
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
CAD 5 coronary artery disease
FMD 5 flow-mediated dilation
MDA 5 malondialdehyde
NMD 5 nitroglycerin-mediated dilation
NO 5 nitric oxide
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Plasma MDA, a marker of lipid peroxidation, was measured
in duplicate by HPLC and fluorescence detection, as pre-
viously described (39).
Treatment and follow-up. After assessment of endothelial
function at baseline, patients were randomly assigned to one
of three groups: placebo group (n 5 25); folic acid only
group (n 5 25)—5 mg/day; folic acid plus antioxidants
group (n 5 25)—folic acid 5 mg/day plus vitamin C 2 g/day
and vitamin E (d-alpha-tocopheryl acetate) 800 IU/day.
Treatment assignments were blinded, with matching pla-
cebo capsules. The assigned treatment was continued for
four months. Compliance was assessed by pill count and was
defined as consumption of .80% of the vitamin capsules.
Patients were instructed to avoid concomitant “open-label”
vitamin or antioxidant use during the study. The study was
conducted after folic acid fortification had been introduced
in Canada in harmony with the U.S. levels (40). All other
medications were held constant throughout the study, if
possible. None of the smokers quit during the study.
Patients underwent follow-up endothelial function and
biochemical measurements after four months.
Statistical analysis. The baseline characteristics of the
three groups were compared using one-way analysis of
variance (ANOVA) for continuous variables and the chi-
square test for categoric variables. The primary end point—
the effect of treatment on endothelium-dependent FMD
and endothelium-independent NMD over time—was as-
sessed by two-way repeated measures ANOVA on an
intention-to-treat basis. The change in the primary end
point within each treatment group was compared with the
corresponding change in the placebo group. Post hoc
comparisons between treatment groups were carried out
with a Bonferroni correction for multiple comparisons.
Secondary end points—the effects of treatment on homo-
cysteine, folate, vitamin B12, lipids and MDA over time—
were also assessed by two-way repeated measures ANOVA,
with Bonferroni correction where appropriate. As homocys-
teine, folate and vitamin B12 values were skewed, a loga-
rithmic transformation was performed, and the results were
expressed as geometric mean values. Linear regression was
used to assess the relation between the change in FMD and
the change in homocysteine, folate and MDA. A general
linear model with backward elimination was used to assess
clinical and biochemical predictors of the change in FMD.
Categoric and continuous variables, including baseline ho-
mocysteine and folate levels and all the clinical characteris-
tics in Table 1, were included in the model. Two-sided p
values ,0.05 were considered to indicate statistical signifi-
cance. Continuous data are expressed as the mean value 6
SD, unless stated otherwise.
RESULTS
Characteristics of the patients. The study group consisted
of 75 patients (16 women and 59 men, mean age 59 6 10
years). The baseline clinical and angiographic characteristics
for the three groups of patients are shown in Table 1. The
only significant difference among the groups was less
angiotensin-converting enzyme (ACE) inhibitor use in the
folic acid plus antioxidants group. Lipid-lowering therapy
was equally distributed among the groups. Use of ACE
inhibitors and lipid-lowering therapy did not significantly
change at follow-up.
Effects on plasma homocysteine, B vitamin, lipid and
MDA levels. Plasma total homocysteine, folate, vitamin
B12, serum lipid and plasma MDA levels at baseline and
Table 1. Clinical and Angiographic Characteristics of the Study Patients
Placebo Group
(n 5 25)
Folic Acid Only
Group
(n 5 25)
Folic Acid Plus
Antioxidants Group
(n 5 25)
Age (yr) 60.6 6 8.6 57.2 6 9.8 58.8 6 11.6
Female gender 16% 24% 24%
Current smoker 24% 24% 16%
History of hypertension 44% 44% 52%
Previous MI 56% 44% 56%
Previous PTCA 64% 52% 48%
Previous CABG 28% 32% 44%
Aspirin use 88% 80% 84%
Beta-blocker use 72% 84% 76%
Calcium channel blocker use 44% 20% 44%
Lipid-lowering therapy 56% 52% 52%
ACE inhibitors 20% 36% 4%†
No. of vessels with disease
1 40% 40% 28%
2 32% 24% 16%
3 28% 36% 56%
Mean LVEF (%) 64.9 6 12.3 61.3 6 18.0 66.4 6 9.9
Serum creatinine (mmol/liter)* 100 6 19 95 6 20 96 6 23
*To convert values for creatinine to mg/dl, divide by 88.4. †p , 0.01 vs. folic acid only group. Data are presented as the mean
value 6 SD or percentage of patients.
ACE 5 angiotensin converting enzyme; CABG 5 coronary artery bypass graft surgery; LVEF 5 left ventricular ejection
fraction; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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follow-up are shown in Table 2. There were no significant
differences between the three groups at baseline.
Overall, the geometric mean value of the baseline plasma
homocysteine level was 12.1 mmol/liter. Only 23% of the
patients had hyperhomocysteinemia (.15 mmol/liter) at
baseline. As compared with baseline levels, homocysteine
levels were reduced by 11% in the folic acid only group (p 5
0.001 vs. baseline) and by 9% in the folic acid plus
antioxidants group (p 5 0.02 vs. baseline) at follow-up.
However, the homocysteine-lowering effects of the two
active treatment groups were not significantly different from
those of the placebo group (p 5 0.23 for folic acid vs.
placebo; p 5 0.56 for folic acid plus antioxidants vs.
placebo).
Overall, the geometric mean value of the baseline plasma
folate level was 14.5 nmol/liter (6.4 mg/liter). No patient
was folate deficient (,6.3 nmol/liter [2.8 mg/liter]) at
baseline. The increase in plasma folate levels from baseline
was significantly greater in the folic acid only group (475%,
p , 0.001) and in the folic acid plus antioxidants (438%,
p , 0.001) group as compared with the placebo group.
Plasma vitamin B12 and serum lipids did not change
significantly in any group. In contrast, plasma MDA levels
significantly fell in the folic acid plus antioxidants group, but
remained unchanged in the placebo and folic acid only
groups (p , 0.05 vs. placebo and folic acid only groups).
Effects on FMD and NMD. Basal heart rate, blood
pressure, end-diastolic brachial artery diameters, brachial
artery flow and reactive hyperemia were similar in each
group at the baseline and follow-up (Table 3).
Baseline FMD was similarly impaired in the three groups
(Table 3). Flow-mediated dilation did not change in the
placebo group. In contrast, FMD significantly improved
from 3.2 6 3.6% to 5.2 6 3.9% in the folic acid only group
(Table 3; p 5 0.003 vs. baseline). In the folic acid plus
antioxidants group, there was a trend toward improvement
in FMD (2.6 6 2.4% to 4.0 6 3.7%; p 5 0.14 vs. baseline).
When using two-way (treatment group vs. time) repeated
Table 2. Effects on Plasma Homocysteine, Plasma Folate, Plasma Vitamin B12, Serum Lipids
and Plasma Malondialdehyde Levels
Variable
Placebo Group
(n 5 25)
Folic Acid Only
Group
(n 5 25)
Folic Acid Plus
Antioxidants Group
(n 5 25)
Plasma homocysteine (mmol/liter),
geometric mean (95% CI)
Baseline 12.1 (11.0–13.4) 12.3 (11.0–13.7) 11.8 (10.3–13.6)
Follow-up 11.8 (10.5–13.3) 10.9 (9.8–12.2)\ 10.8 (9.3–12.5)\
Plasma folate (nmol/liter),*
geometric mean (95% CI)
Baseline 14.7 (12.9–16.8) 13.8 (11.8–16.1) 14.9 (13.3–16.8)
Follow-up 15.6 (13.2–18.4) 79.2 (49.5–126.7)¶ 80.1 (53.5–119.9)¶
Plasma vitamin B12 (pmol/liter),†
geometric mean (95% CI)
Baseline 218 (201–238) 227 (204–253) 229 (208–252)
Follow-up 213 (192–238) 225 (200–252) 208 (188–231)
Total cholesterol (mmol/liter),‡
arithmetic mean (95% CI)
Baseline 5.2 (4.9–5.5) 5.3 (4.9–5.6) 5.4 (4.9–5.9)
Follow-up 5.2 (4.9–5.5) 5.4 (5.0–5.7) 5.4 (5.0–5.9)
LDL cholesterol (mmol/liter),‡
arithmetic mean (95% CI)
Baseline 3.3 (3.1–3.6) 3.5 (3.1–3.8) 3.5 (3.0–3.9)
Follow-up 3.2 (2.9–3.5) 3.5 (3.1–3.8) 3.4 (3.1–3.8)
HDL cholesterol (mmol/liter),‡
arithmetic mean (95% CI)
Baseline 0.9 (0.8–1.0) 0.9 (0.8–1.0) 0.9 (0.8–1.0)
Follow-up 1.0 (0.9–1.1) 1.0 (0.8–1.1) 1.0 (0.9–1.1)
Triglycerides (mmol/liter),§
arithmetic mean (95% CI)
Baseline 2.5 (1.9–3.1) 2.1 (1.7–2.4) 2.3 (2.0–2.7)
Follow-up 2.3 (1.9–2.8) 2.2 (1.8–2.6) 2.3 (1.9–2.7)
Malondialdehyde (nmol/ml),
arithmetic mean (95% CI)
Baseline 0.83 (0.71–0.96) 0.89 (0.76–1.02) 0.94 (0.80–1.08)
Follow-up 0.83 (0.70–0.96) 0.89 (0.76–1.02) 0.82 (0.68–0.95)#
*To convert values for folate to mg/liter, divide by 2.266. †To convert values for vitamin B12 to ng/liter, divide by 0.7378. ‡To
convert values for total cholesterol, LDL cholesterol and HDL cholesterol to mg/dl, divide by 0.02586. §To convert values for
triglycerides to mg/dl, divide by 0.01129. \p , 0.05 vs. baseline. ¶p , 0.001 vs. placebo group. #p , 0.05 vs. placebo group and
folic acid only group.
CI 5 confidence interval; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
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measures ANOVA, we found no significant treatment
group effect (p 5 0.34), but a highly significant time effect
(p 5 0.0004). Overall, there was a significant interaction
between treatment group and time (p 5 0.036), indicating
a significant difference between the three treatment groups
with regard to the change in FMD. The improvement in
FMD was significantly greater in the folic acid only group as
compared with the placebo group (Fig. 1; p 5 0.04 folic acid
only vs. placebo), whereas the improvement in the folic acid
plus antioxidants group was not significantly different from
that in the placebo or folic acid only group (Fig. 1; p 5 0.45
for folic acid plus antioxidants vs. placebo, p . 0.5 for folic
acid plus antioxidants vs. folic acid). Similar results were
obtained after adjusting for differences in baseline ACE
inhibitor use by analysis of covariance. Endothelium-
independent NMD remained unchanged in each group
(Table 3).
Predictors of improvement in FMD. The improvement
in FMD in the folic acid group was significantly correlated
to the reduction in plasma homocysteine levels (r 5 0.5, p 5
0.01), but not to the change in plasma folate or MDA. In
contrast, there was no significant relation between the
change in endothelial function and changes in plasma
homocysteine, folate or MDA in the folic acid plus anti-
oxidants group. A general linear model was used to deter-
mine predictors of improvement in endothelial function.
Treatment group (p 5 0.04), previous revascularization
(p , 0.03) and previous myocardial infarction (p , 0.03)
were significant predictors of a change in endothelial func-
tion. In contrast, gender, smoking, hypertension, medica-
tions (including lipid-lowering therapy or ACE inhibitors)
and baseline levels of homocysteine and folate were not
significant predictors.
Follow-up, side effects and compliance. During follow-
up, the only cardiovascular events were unstable angina in
three patients (one in each group). In general, the study
Table 3. Hemodynamic Data, Brachial Artery End-Diastolic Diameters and Flow, Flow-
Mediated Dilation and Nitroglycerin-Mediated Dilation
Placebo Group
(n 5 25)
Folic Acid Only
Group
(n 5 25)
Folic Acid Plus
Antioxidants Group
(n 5 25)
Basal hemodynamic data
Heart rate (min21)
Baseline 57 6 10 60 6 10 59 6 10
Follow-up 59 6 7 60 6 11 61 6 10
Systolic blood pressure (mm Hg)
Baseline 132 6 17 132 6 20 134 6 16
Follow-up 133 6 17 130 6 18 138 6 17
Diastolic blood pressure (mm Hg)
Baseline 79 6 10 81 6 10 81 6 11
Follow-up 79 6 12 79 6 9 84 6 9
Brachial artery measurements
Basal end-diastolic diameter (mm)
Baseline 4.27 6 0.91 4.44 6 0.98 4.38 6 0.77
Follow-up 4.26 6 0.91 4.36 6 0.87 4.34 6 0.77
Basal brachial artery flow (ml/min)
Baseline 138 6 68 155 6 89 151 6 123
Follow-up 141 6 68 168 6 84 164 6 107
Reactive hyperemia (%)
Baseline 312 6 140 305 6 144 343 6 194
Follow-up 394 6 226 390 6 286 355 6 275
Flow-mediated dilation (%)
Baseline 2.7 6 3.3 3.2 6 3.6 2.6 6 2.4
Follow-up 2.9 6 3.7 5.2 6 3.9* 4.0 6 3.7
Nitroglycerin-mediated dilation (%)
Baseline 12.5 6 7.0 11.7 6 6.2 13.8 6 7.8
Follow-up 13.5 6 6.0 12.9 6 4.8 14.9 6 9.2
*p 5 0.003 vs. baseline; p 5 0.04 vs. placebo group. Data are presented as the mean value 6 SD.
Figure 1. Mean (6SE) change in FMD after four months of therapy in the
three treatment groups: placebo group (n 5 25); folic acid only group (n 5
25); and folic acid plus antioxidants group (n 5 25) (p 5 0.036 for overall
comparison of the three groups). Compared with placebo, folic acid alone
significantly improved FMD after four months (p 5 0.04). In contrast, the
improvement in the folic acid plus antioxidants group was not significantly
different from that in the placebo group (p 5 0.45) or the folic acid only
group (p . 0.5).
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medication was well tolerated. Side effects were noted in
seven patients (two in the placebo group, four in the folic
acid group and one in the folic acid plus antioxidants group)
and were severe enough to discontinue the medication in
four patients (two in the placebo group, one in the folic acid
group and one in the folic acid plus antioxidants group).
Side effects included abdominal cramps, diarrhea and rash.
On the basis of their pill counts, seven patients (9%) were
thought to be noncompliant with their study medications
(three in the placebo group, two in the folic acid alone group
and two in the folic acid plus antioxidants group). Although
these noncompliant patients were included in our primary
intention-to-treat analysis, excluding them did not change
the overall results of the study.
DISCUSSION
Our study shows that four months of folic acid supplemen-
tation (5 mg/day) significantly improves endothelium-
dependent FMD in patients with established CAD and
normal or mildly elevated levels of plasma homocysteine.
Effect of homocysteine on endothelial function. There is
experimental (11–13) and clinical (15–17,27,41,42) evi-
dence suggesting that homocysteine causes endothelial dys-
function, which is a key step in the development and
progression of atherosclerosis (43). Normally, the vascular
endothelium plays an integral role in preventing atheroscle-
rosis through the production of nitric oxide (NO) (44).
Experimentally, homocysteine causes endothelial cell dam-
age (11), impaired release of NO (12), increased inactivation
of NO (26) and impaired endothelium-dependent vasomo-
tor function (13). Endothelium-dependent FMD, which is
dependent on the release of endothelium-derived NO, is
impaired in children with homocysteinuria (15) and adults
with mild to moderate elevations of homocysteine (16,17).
In addition, experimentally raising plasma homocysteine
levels with an oral methionine load leads to an acute,
transient impairment of FMD in healthy subjects
(27,29,41,42).
Effect of folic acid supplementation on endothelial func-
tion. Given its reproducibility, measurement of FMD is
useful for studying the potential reversibility of endothelial
dysfunction with various antiatherogenic treatments
(35,36). Our patients had established coronary atheroscle-
rosis and several risk factors, all associated with abnormal
FMD (34–36). Regardless of the underlying cause, folic
acid supplementation significantly improved endothelial
dysfunction in our patients. The improvement was modest
and, on average, did not restore vascular reactivity to the
normal range (45). However, this degree of improvement is
similar to the effects seen with statins (46) and ACE
inhibitors (47) in patients with CAD. As statins and ACE
inhibitors are associated with reduced cardiovascular events
in large-scale trials, the degree of improvement in endothe-
lial function seen with folic acid in our study may have
clinical relevance.
In contrast to our findings, two previous studies failed to
demonstrate improvement in endothelial function with folic
acid supplementation in patients on dialysis (48,49). These
conflicting results likely reflect differences in their study
group, which had end-stage renal disease and marked
hyperhomocysteinemia, without established atherosclerosis.
In contrast, two recent studies have determined that short-
term folic acid supplementation could improve endothelial
function in patients with familial hypercholesterolemia and
normal homocysteine levels (50) and in healthy subjects
with hyperhomocysteinemia (51). Our results extend these
vascular benefits of folic acid to patients with established
CAD with normal or mildly elevated homocysteine levels.
Effect of folic acid on homocysteine lowering. In our
study, folic acid alone (5 mg) produced a modest 11%
reduction in homocysteine levels after four months. Previ-
ous studies have shown that folic acid in doses of 0.4 to
10 mg can lower homocysteine levels to varying degrees
(18–25). Our results contradict the 23% reduction seen in
the Homocysteine Lowering Trialists’ meta-analysis (23),
but are in keeping with the 11% to 14% reduction seen
when patients with CAD consumed fortified breakfast
cereals (24). The limited homocysteine lowering seen in our
study was likely related to the relatively low levels of
homocysteine and relatively high folate levels at baseline
(23) and to the confounding effect of folate fortification
(23,33,52). When designing our study in 1996, the ideal
dose of folic acid was unknown (32). We chose a daily dose
of 5 mg on the basis of its efficacy in healthy subjects (18)
and vascular patients (20,22), as there were concerns about
the efficacy of low dose folic acid (0.4 mg) in patients with
CAD (2). Further evidence suggests that the homocysteine-
lowering effects of low dose folic acid (,0.5 mg) are similar
to higher doses (.3 mg) (23,25,32).
Potential mechanisms underlying the improvement in
endothelial function. The improvement in endothelial
function seen with folic acid was likely mediated through
multiple mechanisms. Given that this improvement corre-
lated with the reduction in homocysteine levels, we hypoth-
esize that lowering homocysteine levels prevented
homocysteine-induced endothelial injury, impaired NO
release or inactivation of NO, or all of these. However,
folic acid likely has beneficial effects on NO availability
that are independent of its homocysteine-lowering effect.
For example, folic acid can reverse endothelial dysfunction
in experimental hyperhomocysteinemia (42), and
5-methyltetrahydrofolate, the active form of folic acid, can
restore endothelial function in familial hypercholesterolemia
(53) without lowering homocysteine levels. Folic acid may
increase NO formation by stimulating the recycling of
tetrahydrobiopterin, an essential cofactor of endothelial NO
synthase (54). Alternatively, folates can prevent the oxida-
tive degradation of NO by reducing superoxide generation
from NO synthase or xanthine oxidase (53). Thus, folic acid
may restore endothelial function by modulating NO forma-
tion or degradation, or both.
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Effect of folic acid with antioxidant vitamins on endo-
thelial function. There is experimental evidence that
homocysteine-induced endothelial injury is mediated
through oxidative stress (11,12,14,26). In vitro studies
suggest that homocysteine generates reactive oxygen species,
including superoxide anion and hydroxyl radical, which may
cause endothelial dysfunction through lipid peroxidation or
by reducing the availability of NO, or both (11,12,14,26).
Thus, it was surprising that the folic acid plus antioxidants
did not significantly improve endothelial function, whereas
folic acid alone did, despite the beneficial effects of com-
bined therapy on lipid peroxidation. However, as the two
responses on FMD were not significantly different from
each other (p . 0.5 for folic acid plus antioxidants vs. folic
acid alone; Fig. 1), we cannot conclude that the folic
acid–antioxidants combination was less effective than folic
acid alone. Importantly, our study was not sufficiently
powered to indicate that folic acid was superior to the
combination therapy. In contrast to our findings, recently it
has been determined that pretreatment with vitamin C,
alone (27,29) or with vitamin E (28), can prevent acute
impairment in endothelial function in experimentally in-
duced hyperhomocysteinemia. Moreover, long-term vita-
min C supplementation has been shown to significantly
improve FMD in patients with CAD (55). Although our
discordant findings may simply reflect an insufficient sample
size, the possibility of an unfavorable interaction between
vitamins C and E and folic acid, or a prooxidant effect,
cannot be excluded. It is also important to recognize that
vitamin E has failed to have beneficial effects on endothelial
function in patients with coronary atherosclerosis (56,57),
and recently, two important mega-trials have failed to show
a reduction in cardiovascular events with vitamin E (58,59).
Study limitations. First, many patients were smokers,
taking lipid-lowering therapy or ACE inhibitors, which
could affect FMD. However, further analysis suggests that
these factors, including the unequal distribution of baseline
ACE inhibitor use, did not influence our results. Second,
our findings are limited to patients with established coro-
nary atherosclerosis and “average” homocysteine levels.
Therefore, these results cannot be extrapolated to the
general population or to subjects with marked hyperhomo-
cysteinemia. Finally, we studied peripheral artery function
as a surrogate vascular end point, and thus our findings
cannot be directly applied to other vascular beds and may
not imply clinical benefit. However, endothelial dysfunction
is often a generalized process (35), and endothelial dysfunc-
tion of the brachial artery is closely related to coronary
endothelial dysfunction (35) and the extent of coronary
atherosclerosis (60). Therefore, our findings may have
relevance to the coronary circulation. By improving endo-
thelial dysfunction and NO bioavailability, folic acid may
potentially modify the atherogenic process and reduce
cardiovascular events (61).
Conclusions and implications. We have shown that four
months of folic acid supplementation can significantly
improve endothelial dysfunction in patients with established
coronary atherosclerosis. These results provide further sup-
port for the potential therapeutic role of folic acid in CAD.
However, one must await the results of large-scale clinical
trials to determine whether folic acid will reduce cardiovas-
cular morbidity and mortality in patients with established
CAD.
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